Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
affirmatively, Akt, alvespimycin, androgen, antagonism, antagonist, antigen, ASCO, ascribed, Astex, AstraZeneca, attacking, authoritative, bone, Budget, chaperone, chaperoned, chose, circulating, clause, clearer, cMet, cohort, competitor, composition, Conference, Conservation, convey, cyclopamine, deadline, Deduct, deductibility, deny, died, disabled, DiscoverEase, docetaxel, dramatically, duration, elderly, encumber, EORTC, Error, evolution, exacerbate, exemption, exert, exploit, export, extremely, FDAAA, featuring, FIN, folded, formally, franchise, GAAP, geldanamycin, Gleevec, hierarchy, hormone, HRPC, hydrochloride, imatinib, Importantly, inappropriate, inexpensive, inInternal, injunctive, interstate, interventional, Justice, kinase, levy, linked, logo, malignancy, malignant, melanoma, men, mitigate, MMA, Modernization, necessitate, necessitating, Nominating, noncontrolling, nonrefundable, Notwithstanding, occasionally, Occupational, orderly, organizational, orphan, outlined, pendency, physician, pivotal, prescription, pretreated, principle, problem, prohibited, proven, qui, radiographic, rare, ratified, rational, rebate, recall, reconciliation, reformulate, regained, removal, reoccurrence, representational, Reseller, Resource, respond, retaspimycin, revoke, revoked, seize, seizure, Senate, shortly, skin, Smoothened, soft, stability, stabilization, stable, Steve, STS, subtenant, sued, sunitinib, sustain, Sutent, synergy, tam, tanespimycin, Taxotere, tender, testosterone, twenty, unapproved, unbenefited, underwent, undesignated, unfair, unmutated, unobtainable, unreasonable, unresectable, untitled, unused, user, vehicle, vendor, violate, voluntary, waiting, waive, waived, warning, weaken, week, women
Removed:
added, agency, assign, attracting, avoid, biochemical, budgetary, certificate, certification, cessation, challenged, delivery, detailed, discrete, duly, Ernst, Europe, eventual, favorable, functional, generating, hand, harry, hire, hixson, II, implemented, improper, incorporation, instituted, interaction, jr, led, liquidation, list, listed, LLP, long, michael, negotiating, nonstatutory, optimization, optimizing, permanent, preserve, promptly, proof, purity, realize, recover, recoverable, rendered, requirement, resolved, restrict, reviewed, revised, Rule, run, satisfactory, separately, shortened, skilled, studied, succeed, suit, surveillance, susceptible, technological, thereto, thereunto, treated, trend, Trust, typical, undergoing, undersigned, uneconomical, unenforceable, venuti, waste, Young
Filing tables
Filing exhibits
- 10-K Annual report
- 4.1 Form of Common Stock Certificate
- 21.1 Subsidiaries of the Registrant
- 23.1 Consent of Ernst & Young LLP
- 31.1 Certification of Principal Executive Officer
- 31.2 Certification of Principal Financial Officer
- 32.1 Statement of Principal Executive Officer
- 32.2 Statement of Principal Financial Officer
Related press release
INFIQ similar filings
Filing view
External links
EXHIBIT 32.1
STATEMENT PURSUANT TO 18 U.S.C. §1350
Pursuant to 18 U.S.C. §1350, the undersigned certifies that this Annual Report on Form 10-K for the period ended December 31, 2007 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Infinity Pharmaceuticals, Inc.
| Dated: March 13, 2008 | /s/ STEVEN H. HOLTZMAN | |||
Steven H. Holtzman Chief Executive Officer (Principal executive officer) | ||||
A signed original of this written statement required by Section 906 has been provided to Infinity Pharmaceuticals, Inc. and will be retained by Infinity Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.